OTCMKTS:NWCI

NewCardio Competitors

$0.0034
0.00 (0.00 %)
(As of 04/13/2021 12:00 AM ET)
Add
Compare
Today's Range
$0.00
Now: $0.00
$0.00
50-Day Range N/A
52-Week Range
$0.00
Now: $0.00
$0.00
VolumeN/A
Average Volume78,216 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
Beta4.43

Competitors

NewCardio (OTCMKTS:NWCI) Vs. MDT, SONVY, VAR, MASI, GNGBY, and LIVN

Should you be buying NWCI stock or one of its competitors? Companies in the industry of "electromedical equipment" are considered alternatives and competitors to NewCardio, including Medtronic (MDT), Sonova (SONVY), Varian Medical Systems (VAR), Masimo (MASI), Getinge (GNGBY), and LivaNova (LIVN).

NewCardio (OTCMKTS:NWCI) and Medtronic (NYSE:MDT) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, risk, earnings, dividends, institutional ownership, profitability and valuation.

Institutional and Insider Ownership

79.2% of Medtronic shares are owned by institutional investors. 0.5% of Medtronic shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Risk & Volatility

NewCardio has a beta of 4.43, meaning that its share price is 343% more volatile than the S&P 500. Comparatively, Medtronic has a beta of 0.7, meaning that its share price is 30% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for NewCardio and Medtronic, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
NewCardio0000N/A
Medtronic031812.91

Medtronic has a consensus price target of $124.2692, suggesting a potential upside of 0.30%. Given Medtronic's higher possible upside, analysts plainly believe Medtronic is more favorable than NewCardio.

Profitability

This table compares NewCardio and Medtronic's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
NewCardioN/AN/AN/A
Medtronic12.69%9.71%5.30%

Valuation and Earnings

This table compares NewCardio and Medtronic's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NewCardioN/AN/AN/AN/AN/A
Medtronic$28.91 billion5.78$4.79 billion$4.5926.99

Medtronic has higher revenue and earnings than NewCardio.

Summary

Medtronic beats NewCardio on 9 of the 10 factors compared between the two stocks.

NewCardio (OTCMKTS:NWCI) and Sonova (OTCMKTS:SONVY) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, earnings, analyst recommendations, dividends, institutional ownership and profitability.

Profitability

This table compares NewCardio and Sonova's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
NewCardioN/AN/AN/A
SonovaN/AN/AN/A

Analyst Ratings

This is a breakdown of current ratings and target prices for NewCardio and Sonova, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
NewCardio0000N/A
Sonova06302.33

Volatility and Risk

NewCardio has a beta of 4.43, indicating that its stock price is 343% more volatile than the S&P 500. Comparatively, Sonova has a beta of 0.7, indicating that its stock price is 30% less volatile than the S&P 500.

Earnings & Valuation

This table compares NewCardio and Sonova's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NewCardioN/AN/AN/AN/AN/A
Sonova$2.96 billion6.18$489.96 million$1.4938.08

Sonova has higher revenue and earnings than NewCardio.

Institutional and Insider Ownership

1.1% of Sonova shares are held by institutional investors. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Sonova beats NewCardio on 3 of the 4 factors compared between the two stocks.

Varian Medical Systems (NYSE:VAR) and NewCardio (OTCMKTS:NWCI) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, earnings, analyst recommendations, institutional ownership, risk, profitability and valuation.

Profitability

This table compares Varian Medical Systems and NewCardio's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Varian Medical Systems8.50%18.45%8.08%
NewCardioN/AN/AN/A

Valuation & Earnings

This table compares Varian Medical Systems and NewCardio's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Varian Medical Systems$3.17 billion5.13$269.20 million$3.9145.29
NewCardioN/AN/AN/AN/AN/A

Varian Medical Systems has higher revenue and earnings than NewCardio.

Risk and Volatility

Varian Medical Systems has a beta of 1.06, meaning that its share price is 6% more volatile than the S&P 500. Comparatively, NewCardio has a beta of 4.43, meaning that its share price is 343% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings and price targets for Varian Medical Systems and NewCardio, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Varian Medical Systems35001.63
NewCardio0000N/A

Varian Medical Systems presently has a consensus price target of $159.3571, indicating a potential downside of 10.00%. Given Varian Medical Systems' higher possible upside, equities analysts plainly believe Varian Medical Systems is more favorable than NewCardio.

Institutional & Insider Ownership

87.0% of Varian Medical Systems shares are held by institutional investors. 0.8% of Varian Medical Systems shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Varian Medical Systems beats NewCardio on 7 of the 8 factors compared between the two stocks.

NewCardio (OTCMKTS:NWCI) and Masimo (NASDAQ:MASI) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, dividends, analyst recommendations, valuation and earnings.

Profitability

This table compares NewCardio and Masimo's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
NewCardioN/AN/AN/A
Masimo20.30%15.75%13.12%

Valuation and Earnings

This table compares NewCardio and Masimo's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NewCardioN/AN/AN/AN/AN/A
Masimo$937.84 million14.12$196.22 million$3.2274.39

Masimo has higher revenue and earnings than NewCardio.

Institutional & Insider Ownership

81.6% of Masimo shares are owned by institutional investors. 11.5% of Masimo shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Risk and Volatility

NewCardio has a beta of 4.43, indicating that its share price is 343% more volatile than the S&P 500. Comparatively, Masimo has a beta of 0.87, indicating that its share price is 13% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current recommendations and price targets for NewCardio and Masimo, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
NewCardio0000N/A
Masimo02502.71

Masimo has a consensus target price of $272.20, indicating a potential upside of 13.63%. Given Masimo's higher probable upside, analysts plainly believe Masimo is more favorable than NewCardio.

Summary

Masimo beats NewCardio on 8 of the 9 factors compared between the two stocks.

NewCardio (OTCMKTS:NWCI) and Getinge (OTCMKTS:GNGBY) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, valuation, analyst recommendations, dividends, earnings, institutional ownership and profitability.

Analyst Ratings

This is a breakdown of recent recommendations for NewCardio and Getinge, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
NewCardio0000N/A
Getinge11502.57

Profitability

This table compares NewCardio and Getinge's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
NewCardioN/AN/AN/A
Getinge10.51%17.30%7.90%

Risk & Volatility

NewCardio has a beta of 4.43, indicating that its share price is 343% more volatile than the S&P 500. Comparatively, Getinge has a beta of 0.83, indicating that its share price is 17% less volatile than the S&P 500.

Valuation & Earnings

This table compares NewCardio and Getinge's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NewCardioN/AN/AN/AN/AN/A
Getinge$2.81 billion2.76$129.29 millionN/AN/A

Getinge has higher revenue and earnings than NewCardio.

Insider & Institutional Ownership

0.0% of Getinge shares are owned by institutional investors. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Getinge beats NewCardio on 6 of the 7 factors compared between the two stocks.

LivaNova (NASDAQ:LIVN) and NewCardio (OTCMKTS:NWCI) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, analyst recommendations, risk, institutional ownership, profitability and earnings.

Valuation and Earnings

This table compares LivaNova and NewCardio's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
LivaNova$1.08 billion3.65$-155,180,000.00$3.0826.42
NewCardioN/AN/AN/AN/AN/A

NewCardio has lower revenue, but higher earnings than LivaNova.

Profitability

This table compares LivaNova and NewCardio's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
LivaNova-21.88%5.55%3.07%
NewCardioN/AN/AN/A

Insider and Institutional Ownership

89.1% of LivaNova shares are held by institutional investors. 0.5% of LivaNova shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Volatility & Risk

LivaNova has a beta of 0.8, indicating that its stock price is 20% less volatile than the S&P 500. Comparatively, NewCardio has a beta of 4.43, indicating that its stock price is 343% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings for LivaNova and NewCardio, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
LivaNova04202.33
NewCardio0000N/A

LivaNova currently has a consensus target price of $69.3333, indicating a potential downside of 14.79%. Given LivaNova's higher possible upside, equities research analysts clearly believe LivaNova is more favorable than NewCardio.

Summary

LivaNova beats NewCardio on 7 of the 9 factors compared between the two stocks.


NewCardio Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Medtronic logo
MDT
Medtronic
2.7$123.90flat$166.66 billion$28.91 billion47.29
Sonova logo
SONVY
Sonova
0.9$56.74flat$18.40 billion$2.96 billion38.08Increase in Short Interest
Varian Medical Systems logo
VAR
Varian Medical Systems
1.3$177.07flat$16.27 billion$3.17 billion60.43
Masimo logo
MASI
Masimo
1.6$239.55flat$13.22 billion$937.84 million62.22Insider Selling
Getinge logo
GNGBY
Getinge
0.6$30.56flat$7.58 billion$2.81 billion25.25Upcoming Earnings
Analyst Upgrade
News Coverage
LivaNova logo
LIVN
LivaNova
1.5$81.37flat$3.99 billion$1.08 billion-18.92Analyst Report
News Coverage
CNMD
CONMED
1.6$130.45flat$3.82 billion$955.10 million-3,261.25
InMode logo
INMD
InMode
1.5$83.53flat$2.68 billion$156.36 million60.09Analyst Downgrade
Outset Medical logo
OM
Outset Medical
1.0$54.50flat$2.34 billionN/A0.00Analyst Upgrade
BioLife Solutions logo
BLFS
BioLife Solutions
2.1$33.59flat$1.16 billion$27.37 million-46.01Insider Selling
Increase in Short Interest
NTUS
Natus Medical
1.1$28.63flat$926.45 million$495.52 million-52.05
AxoGen logo
AXGN
AxoGen
1.5$19.42flat$801.17 million$106.71 million-30.83News Coverage
TransMedics Group logo
TMDX
TransMedics Group
1.6$29.13flat$792.09 million$23.60 million-20.81Increase in Short Interest
Gap Down
SMLR
Semler Scientific
1.2$110.00flat$727.08 million$32.77 million77.46Insider Selling
Decrease in Short Interest
News Coverage
ViewRay logo
VRAY
ViewRay
1.3$4.43flat$691.44 million$87.78 million-4.98
Stereotaxis logo
STXS
Stereotaxis
0.6$8.35flat$603.35 million$28.90 million-75.91
Cutera logo
CUTR
Cutera
1.3$30.78flat$556.07 million$181.71 million-17.01
Zynex logo
ZYXI
Zynex
1.8$15.19flat$523.87 million$45.47 million46.03
Edap Tms logo
EDAP
Edap Tms
1.3$9.06flat$267.82 million$50.23 million-151.00Increase in Short Interest
Second Sight Medical Products logo
EYES
Second Sight Medical Products
0.8$8.24flat$195.07 million$3.38 million-4.31Decrease in Short Interest
BioSig Technologies logo
BSGM
BioSig Technologies
0.5$4.21flat$137.33 millionN/A0.00News Coverage
FONR
FONAR
1.1$17.98flat$117.78 million$85.69 million16.96
IRIDEX logo
IRIX
IRIDEX
0.9$7.41flat$113.61 million$43.45 million-13.47
Soleno Therapeutics logo
SLNO
Soleno Therapeutics
1.9$1.22flat$94.87 millionN/A-1.61Increase in Short Interest
ENDRA Life Sciences logo
NDRA
ENDRA Life Sciences
0.6$2.28flat$94.85 million$10,000.00-1.24Analyst Upgrade
Increase in Short Interest
electroCore logo
ECOR
electroCore
1.4$1.82flat$89.20 million$2.39 million-2.30Decrease in Short Interest
Electromed logo
ELMD
Electromed
1.8$10.09flat$87.13 million$32.47 million24.02Analyst Downgrade
Helius Medical Technologies logo
HSDT
Helius Medical Technologies
1.5$17.56flat$40.28 million$1.50 million-1.00Increase in Short Interest
Fc Global Realty logo
FCRE
Fc Global Realty
0.5$0.10flat$38.87 million$40,000.000.00Gap Up
CHF Solutions logo
CHFS
CHF Solutions
1.7$5.33flat$31.63 million$5.51 million-0.11High Trading Volume
Increase in Short Interest
Viveve Medical logo
VIVE
Viveve Medical
0.9$3.01flat$31.03 million$6.57 million-0.01
ReShape Lifesciences logo
RSLS
ReShape Lifesciences
0.6$4.40flat$27.14 million$15.09 million0.00Gap Up
PEYE
Precision Optics
0.4$1.62flat$21.49 million$9.92 million-16.20
STRR
Star Equity
0.1$3.21flat$16.24 million$114.18 million-1.02
Vaso logo
VASO
Vaso
0.9$0.09flat$15.14 million$75.75 million4.60News Coverage
Gap Up
GTHP
Guided Therapeutics
0.3$0.80flat$10.81 million$40,000.00-3.33Gap Up
Micron Solutions logo
MICR
Micron Solutions
0.3$3.01flat$10.59 million$17.50 million21.50Increase in Short Interest
NIMU
Non-Invasive Monitoring Systems
0.5$0.03flat$2.49 millionN/A0.00Upcoming Earnings
RSLSD
ReShape Lifesciences
0.4N/AN/A$1.94 million$610,000.000.00High Trading Volume
MAGAA
Magna-Lab
0.7$1.09flat$1.29 millionN/A6.06Gap Down
Nexeon MedSystems logo
NXNN
Nexeon MedSystems
0.7$0.55flat$1.12 millionN/A0.00
ARDMQ
Aradigm
0.0$0.05flat$764,000.00N/A0.00
IMRIS logo
IMRSQ
IMRIS
0.5$0.01flat$364,000.00N/A0.00Gap Up
Echo Therapeutics logo
ECTE
Echo Therapeutics
0.5$0.03flat$356,000.00N/A0.00Gap Up
SCIE
SpectraScience
0.5$0.00flat$265,000.00N/A0.00Decrease in Short Interest
News Coverage
Gap Down
ULGX
Urologix
0.6$0.01flat$153,000.00N/A0.00Gap Up
AKSY
Aksys
0.0$0.00flat$0.00N/A0.00
Escalon Medical logo
ESMC
Escalon Medical
0.5$0.40flat$0.00$9.40 million-6.67Increase in Short Interest
Gap Down
HRTT
Heart Tronics
0.0$0.02flat$0.00N/A0.00High Trading Volume
Gap Up
IVVI
Ivivi Technologies
0.0$0.00flat$0.00N/A0.00High Trading Volume
This page was last updated on 4/14/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.